Tobin C. Schilke
2017 - Achaogen
In 2017, Tobin C. Schilke earned a total compensation of $1.8M as Chief Financial Officer at Achaogen.
Compensation breakdown
| Non-Equity Incentive Plan | $84,000 |
|---|---|
| Option Awards | $1,027,908 |
| Salary | $365,000 |
| Stock Awards | $316,753 |
| Other | $9,000 |
| Total | $1,802,661 |
Schilke received $1M in option awards, accounting for 57% of the total pay in 2017.
Schilke also received $84K in non-equity incentive plan, $365K in salary, $316.8K in stock awards and $9K in other compensation.
Rankings
In 2017, Tobin C. Schilke's compensation ranked 6,011th out of 14,666 executives tracked by ExecPay. In other words, Schilke earned more than 59.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,011 out of 14,666 | 59th |
Division Manufacturing | 2,206 out of 5,768 | 62nd |
Major group Chemicals And Allied Products | 694 out of 2,074 | 67th |
Industry group Drugs | 536 out of 1,730 | 69th |
Industry Pharmaceutical Preparations | 422 out of 1,329 | 68th |
Source: SEC filing on April 18, 2018.
Schilke's colleagues
We found five more compensation records of executives who worked with Tobin C. Schilke at Achaogen in 2017.
News
Revance Therapeutics CEO Mark Foley's 2021 pay slips 19% to $7.1M
March 24, 2022
Revance Therapeutics CEO Mark Foley's 2020 pay falls 49% to $8.8M
March 11, 2021
Revance Therapeutics CEO Mark Foley receives $17M in 2019
March 26, 2020
Revance Therapeutics CEO L Browne's 2018 pay jumps 37% to $4.7M
March 25, 2019